CSIMarket Company Name, Ticker, Customers, else..
 
Miromatrix Medical inc   (NASDAQ: MIRO)
Other Ticker:  
 
 
Price: $3.3900 $0.02 0.593%
Day's High: $3.53 Week Perf: 0.59 %
Day's Low: $ 3.36 30 Day Perf:
Volume (M): 632 52 Wk High: $ 0.00
Volume (M$): $ 2,143 52 Wk Avg: $0.00
Open: $3.38 52 Wk Low: $0.00



 Market Capitalization (Millions $) 93
 Shares Outstanding (Millions) 27
 Employees 30
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Miromatrix Medical Inc
Miromatrix Medical Inc. is a biotechnology company based in Minnesota, United States. The company focuses on bioengineering and regenerative medicine solutions for organ transplantation. Miromatrix specializes in developing and using its patented perfusion decellularization and recellularization technologies to create functional organs and tissues for transplantation.

The company's goal is to address the shortage of donor organs by creating a sustainable and scalable method of organ production. Miromatrix's process involves removing the cellular components from animal organs, leaving behind only the extracellular matrix (ECM), a framework that can support tissue growth. The ECM is then recellularized with human cells, allowing the organ to be functional and compatible with the recipient's body.

Miromatrix's main areas of focus are liver, kidney, heart, and lung transplantation, which are some of the most critical and challenging areas in organ transplantation. By using its innovative platform technology, Miromatrix aims to provide a viable alternative to traditional organ transplantation, with the potential to save countless lives and improve the quality of life for patients in need.

In addition to its organ transplantation focus, Miromatrix also explores applications in other areas such as tissue repair, drug screening, and disease modeling. The company collaborates with academic institutions, research organizations, and medical professionals to further advance its technology and explore new possibilities in regenerative medicine.

Overall, Miromatrix Medical Inc. is a pioneering company that combines cutting-edge technology and biology to revolutionize the field of organ transplantation and bring hope to patients in need of life-saving procedures.


   Company Address: 6455 Flying Cloud Drive, Suite 107 Eden Prairie 55344 MN
   Company Phone Number: 942-6000   Stock Exchange / Ticker: NASDAQ MIRO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IOVA   -2.82%    
NVAX   -4.27%    
VCEL   -0.41%    
VXRT   -11.45%    
WINT        12.84% 
IART   -3.92%    
• View Complete Report
   



Fennec Pharmaceuticals Inc

Observing the fourth quarter of 2024 performance, the Biotechnology and Pharmaceuticals company's made a similar performance like a year before

For the most recent fiscal period FENC reached balanced books of $0.00 per share compare to $0.00 a year before and from $-0.21 per share from the preceding quarter. The revenue remained unscathed to $0.00 million from $0.00 million in the comparable quarter a year before and sequentially from $6.97 million.

Biocardia Inc

Breaking down fourth quarter of 2024 numbers, the company's had a similar effort like a year before

For the most recent fiscal period company increased a loss per share of $-1.22 per share compare to $-1.18 a year before and increased loss from $-0.61 per share from the previous quarter. The revenue remained unchanged to $0.00 million from $0.01 million in the corresponding quarter a year before and sequentially from $0.00 million.

Dyadic International Inc

Profitability not reached inspite of bewildering revenue at in the October to December 31 2024 financial interval

For the October to December 31 2024 financial interval DYAI lost money of $-0.05 per share compare to $-0.07 a year before and advanced deficit from $-0.01 per share from the prior reporting period. The revenue rose extensively by 19.058 % to $0.82 million from $0.69 million in the similar reporting period a year before and sequentially Revenue Tumbled by -58.244 % from $1.96 million.

Zura Bio Limited

expenditures were increasing at the Zura Bio Limited in the most recent fiscal period

The Biotechnology and Pharmaceuticals sector consultants start to digest the fourth quarter of 2024 performance. Presently they monitor operating loss of $-15.732 million, from the company, which has not stated any top-line still, for the own October to December 31 2024 reporting season.

Precision Biosciences Inc

Extremely difficult financial reporting period for DTIL during the fourth quarter of 2024 earnings season

For the October to December 31 2024 time-frame DTIL decreased a loss per share of $-1.53 per share compare to $-3.92 a year ago and Income per Share improved from $-2.25 per share from the preceding financial reporting period. The revenue dropped sharply by -90.935 % to $0.64 million from $7.04 million in the same financial reporting period a year ago and sequentially revenue advanced by 10.764 % from $0.58 million.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com